Vernalis (VNLPY) Stock Price, News & Analysis

Vernalis plc, a commercial stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Tuzistra XR for the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of amoxicillin antibiotic for the treatment of tonsillitis and pharyngitis secondary to streptococcus pyogenes in adults and pediatric patients; and frovatriptan for the acute treatment of migraine. It is also has licensing agreement to develop and commercialize various products focused on the U.S. prescription cough-cold market. In addition, the company is developing V158866, a fatty acid amide hydrolase inhibitor for the treatment of pain; CPI-444, an adenosine A2A receptor antagonist, which is in Phase I/Ib clinical trial to treat patients with various solid tumors; and AUY922, an intravenous Hsp90 inhibitor for treating cancer, as well as CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukemia and myelodysplastic syndrome under Phase II trial. Further, it is developing S55746, a selective Bcl-2 inhibitor that is in Phase I study for the treatment of cancer; V158411 molecule; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc.; Biogen Idec; Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc.; Novartis Pharma AG; Servier Research Group; GlaxoSmithKline plc; Genentech; and Tris Pharma Inc. Vernalis plc was incorporated in 1988 and is headquartered in Winnersh, the United Kingdom.